Beam Therapeutics Statistics Share Statistics Beam Therapeutics has 101.16M
shares outstanding. The number of shares has increased by 22.01%
in one year.
Shares Outstanding 101.16M Shares Change (YoY) 22.01% Shares Change (QoQ) 0.72% Owned by Institutions (%) 99.99% Shares Floating 91.26M Failed to Deliver (FTD) Shares 134 FTD / Avg. Volume 0.01%
Short Selling Information The latest short interest is 27.17M, so 27.02% of the outstanding
shares have been sold short.
Short Interest 27.17M Short % of Shares Out 27.02% Short % of Float 30.39% Short Ratio (days to cover) 10.69
Valuation Ratios The PE ratio is -5.42 and the forward
PE ratio is -3.68.
Beam Therapeutics's PEG ratio is
-0.03.
PE Ratio -5.42 Forward PE -3.68 PS Ratio 32.14 Forward PS 41.5 PB Ratio 2.78 P/FCF Ratio -5.73 PEG Ratio -0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Beam Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.82,
with a Debt / Equity ratio of 0.22.
Current Ratio 4.82 Quick Ratio 4.82 Debt / Equity 0.22 Debt / EBITDA -0.42 Debt / FCF -0.45 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $161.62K Profits Per Employee $-958.63K Employee Count 393 Asset Turnover 0.06 Inventory Turnover n/a
Taxes Income Tax 39K Effective Tax Rate -0.01%
Stock Price Statistics The stock price has increased by -22.09% in the
last 52 weeks. The beta is 2.23, so Beam Therapeutics's
price volatility has been higher than the market average.
Beta 2.23 52-Week Price Change -22.09% 50-Day Moving Average 18.69 200-Day Moving Average 21.93 Relative Strength Index (RSI) 58.45 Average Volume (20 Days) 2,287,846
Income Statement In the last 12 months, Beam Therapeutics had revenue of 63.52M
and earned -376.74M
in profits. Earnings per share was -4.58.
Revenue 63.52M Gross Profit 63.52M Operating Income -415.57M Net Income -376.74M EBITDA -383.98M EBIT -415.57M Earnings Per Share (EPS) -4.58
Full Income Statement Balance Sheet The company has 281.97M in cash and 161.43M in
debt, giving a net cash position of 120.54M.
Cash & Cash Equivalents 281.97M Total Debt 161.43M Net Cash 120.54M Retained Earnings -1.57B Total Assets 1.39B Working Capital 1B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -347.25M
and capital expenditures -8.95M, giving a free cash flow of -356.19M.
Operating Cash Flow -347.25M Capital Expenditures -8.95M Free Cash Flow -356.19M FCF Per Share -4.33
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -654.25% and -593.13%.
Gross Margin 100% Operating Margin -654.25% Pretax Margin -593.06% Profit Margin -593.13% EBITDA Margin -604.51% EBIT Margin -654.25% FCF Margin -560.77%
